Physician profile
Charlie W Devlin
NPI 1316987860
$2,830.89
in general payments reported to CMS, 2019-2025
18 companies · $18.27 in 2025
The $18.27 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $741 · 2021: $714 · 2022: $215 · 2023: $416 · 2025: $18.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $737.19 | 2019-2023 | |
| Amgen INC. | $589.46 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $489.96 | 2019-2023 | Lifevest |
| Pfizer INC. | $225.97 | 2019-2021 | |
| Astellas Pharma US INC | $203.38 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $185.43 | 2019-2023 | Xarelto |
| Cardiva Medical, INC. | $103.17 | 2022-2023 | Cardiva Vascade 6/7f Vcs |
| E.R. Squibb & Sons, L.L.C. | $55.57 | 2019-2021 | |
| Boston Scientific Corporation | $45.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $41.63 | 2019-2020 | |
| Amarin Pharma, INC. | $34.74 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.61 | 2021 | |
| Cordis US Corp. | $18.27 | 2025 | Mynx Control |
| Regeneron Healthcare Solutions, INC. | $15.62 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.12 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.72 | 2021 | |
| Abbott Laboratories | $13.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlie Devlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.